Health
What to Know About mRNA Vaccines

Health Secretary Robert F. Kennedy, Jr., has repeatedly questioned the safety of mRNA vaccines against Covid-19. Scientists with funding from the National Institutes of Health were advised to scrub their grants of any reference to mRNA. Around the country, state legislatures are considering bills to ban or limit such vaccines, with one describing them as weapons of mass destruction.
While mRNA, or messenger RNA, has received widespread attention in recent years, scientists first discovered it in 1961. They have been studying it and exploring its promise in preventing infectious diseases and treating cancer and rare diseases ever since.
What is mRNA?
A large molecule found in all of our cells, mRNA is used to make every protein that our DNA directs our bodies to build. It does so by carrying information from DNA in the nucleus out to a cell’s protein-making machinery. A single mRNA molecule can be used to make many copies of a protein, but it is naturally programmed to die eventually, said Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University and a co-founder of an RNA therapeutics company.
How do mRNA vaccines work?
Right now, there are three FDA-approved vaccines available that use mRNA, two for Covid-19 and one for R.S.V., or respiratory syncytial virus, in older adults. These vaccines consist of strands of mRNA that code for specific viral proteins.
Say you get a Covid-19 vaccine. The strands of mRNA, packaged into tiny fat particles, go into your muscle and immune cells, said Robert Alexander Wesselhoeft, director of RNA therapeutics at the Gene and Cell Therapy Institute at Mass General Brigham. Protein factories in the cells then take instructions from the mRNA and manufacture a protein like the one found on the surface of a Covid-19 virus. Your body recognizes that protein as foreign, and mounts an immune response.
Most of the mRNA will be gone within a few days, but the body retains a “memory” of it in the form of antibodies, Dr. Coller said. As with other types of vaccines, immunity wanes both over time and as a virus evolves into new variants.
Why are mRNA vaccines being used now?
In the mid-2000s, scientists at the University of Pennsylvania figured out how to get foreign mRNA into human cells without it degrading first. That enabled researchers to develop it for use in vaccines.
The main use for such vaccines right now is to prevent infectious diseases, like Covid-19 and R.S.V., said Dr. Wesselhoeft, who founded a company that develops RNA therapies. The mRNA vaccines can be made very quickly because all of the components, other than the RNA sequence, remain the same across different vaccines.
This feature could be helpful for developing the annual flu vaccine, said Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai, who has previously consulted for Pfizer and CureVac on mRNA therapies. Typically, scientists decide in February or March which influenza virus strains to include in a vaccine that will be rolled out in the United States in September. But by that time, a different strain may be dominant. Because an mRNA vaccine can be manufactured more quickly than the current flu shot, scientists could wait until May or June to see which strains are circulating, Dr. Krammer said, increasing the likelihood the vaccine will be effective.
Do these vaccines have risks?
A common question patients ask is whether an mRNA vaccine can affect their DNA, Dr. Boucher said. The answer is no. Our cells cannot convert mRNA into DNA, which means that it can’t be incorporated into our genome.
The vaccine for Covid-19 can cause muscle aches and flulike symptoms, but these are expected side effects for vaccines generally, Dr. Krammer said.
It’s been more than four years since the Covid-19 vaccine was first rolled out “and there are not long-term safety signals,” said Dr. Adam Ratner, a pediatric infectious disease specialist in New York. Many parents were concerned about myocarditis, an inflammation of the heart muscle that was reported as a possible side effect of the vaccine. But, Dr. Ratner said, the risk of such inflammation from an actual Covid-19 infection, or of long Covid or multisystem inflammatory syndrome in children, was far greater.
What else can mRNA be used for?
Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, autoimmune disorders like Type 1 diabetes and rare diseases like cystic fibrosis, a genetic condition that results in excessively thick, sticky mucus that can plug the airways and damage the lungs.
In cancer, the idea is that the mRNA codes for a tumor protein that the immune system will recognize as foreign, telling the body to attack the tumor. In a genetic disorder like cystic fibrosis, it codes for a functioning version of a deficient protein to replace the faulty one and restore the mucus to healthy state.
A paper in the journal Nature earlier this year showed that an experimental mRNA vaccine for pancreatic cancer provoked an immune response in some patients after they had undergone surgery for the cancer. Patients who experienced that immune response lived longer without cancer than patients who did not.
Another recent paper showed that, in monkeys, an inhaled mRNA therapy could produce a protein needed to form cilia, the hairlike structures that line our airways and move mucus out of them. These proteins malfunction in a debilitating respiratory disorder called primary ciliary dyskinesia.
This research is still in early stages: The pancreatic cancer study, a Phase I trial, included only 16 patients, and there may have been other differences between the two groups that accounted for the different survival times. There is a long history of research showing that interventions may lead to immune responses without actually changing patients’ outcomes, explained Dr. Steven Rosenberg, chief of the surgery branch at the National Cancer Institute and an expert in cancer immunotherapy.
Dr. Richard Boucher, a pulmonologist at the University of North Carolina at Chapel Hill, noted that for lung diseases, it’s extremely difficult to safely get the particles carrying mRNA into exactly the right cells.
In general, Dr. Ratner said, mRNA vaccines are “exciting” in that they offer hope for disease treatments where prior technologies have failed. But mRNA therapy is still a drug technology like any other: In some diseases it likely will work, he said, “and in other cases it probably won’t.”

Health
We Tried Three Doctor-Approved, Ozempic-Friendly Recipes | Woman's World

Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Weight-loss medications may also benefit common medical problem, study finds

Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and obesity, have been shown to have the surprising secondary benefit of reducing alcohol intake.
A team of international researchers from Ireland and Saudi Arabia followed 262 adult patients with obesity who started taking two GLP-1 medications: liraglutide or semaglutide.
Among the regular drinkers, weekly alcohol intake decreased by 68%, from approximately 23 units of alcohol to around 8 units.
WEIGHT LOSS, DIABETES DRUGS CAN CAUSE MOOD CHANGES: WHAT TO KNOW ABOUT BEHAVIORAL SIDE EFFECTS
The findings were recently published in the journal Diabetes, Obesity and Metabolism and were also presented last week at the European Congress on Obesity in Spain.
GLP-1 agonists mimic a hormone called GLP-1, which is released from the gastrointestinal system after eating, according to study co-author Carel Le Roux, a professor at University College Dublin.
Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists have been shown to have the surprising secondary benefit of reducing alcohol intake. (iStock)
These medications activate GLP-1 receptors in the brain, decreasing the sense of “reward” people feel after eating or drinking, eventually leading to reduced cravings for both food and alcohol, he told Fox News Digital.
“It is this commonality of function that suggests the GLP-1 receptors in the brain may be a therapeutic target for not just the disease of obesity, but also for alcohol use disorder,” the professor said.
Study findings
Before the participants started the weight-loss drugs, they self-reported their weekly alcohol intake, then were categorized as non-drinkers, rare drinkers or regular drinkers.
Approximately 72% had at least two follow-up visits and 68% reported regular alcohol consumption.
WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY
After starting the weight-loss medications, the participants’ weekly average alcohol intake decreased by almost two-thirds overall — from approximately 11 units of alcohol to four units after four months of treatment with the GLP-1 agonists.
The reduction in alcohol use was comparable to the decrease that can be achieved by nalmefene, a drug that decreases the “buzz” feeling in people with alcohol use disorder in Europe, according to the researchers.

Among the regular drinkers, weekly alcohol intake decreased by 68%, from approximately 23 units of alcohol to around 8 units. (iStock)
For the 188 patients who were followed over an average of four months, none had increased their alcohol intake after starting the weight-loss medications.
Patients reported that after an evening meal, they were too full to have their usual drink — and when they did drink, they reported becoming full extremely quickly and drinking at a slower pace, Le Roux noted.
“The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder.”
This suggests that the experience was less enjoyable, partly due to the reduced rate of alcohol absorption.
Some patients also reported that they didn’t enjoy the flavor of the alcoholic beverages as much, and also that hangovers were much worse.
All of these experiences showed that the weight-loss medications create “guard rails” that prevent most patients from drinking excessively, giving them a degree of control over their alcohol intake, according to Le Roux.

After starting the weight-loss medications, the participants’ weekly average alcohol intake decreased by almost two-thirds overall. (iStock)
“The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder — the GLP-1 receptor,” the professor told Fox News Digital.
“This finding potentially opens the possibility of an entirely new pharmacological treatment paradigm, which could be used in conjunction with conventional methods, such as behavior therapy and group support.”
Potential limitations
The study was limited by its relatively small number of patients, the researchers acknowledged.
Also, the researchers were not able to verify the participants’ self-reported alcohol intake, and roughly one-third of them were not available for follow-up.
SEMAGLUTIDE FOUND TO HAVE SHOCKING BENEFIT FOR LIVER DISEASE PATIENTS IN NEW STUDY
There was also no control group, which means the researchers couldn’t prove that taking weight-loss medication reduces alcohol intake.

The main advantage of GLP-1 agonists is that they only need to be taken once a week and continue to work for the entire week. (iStock)
“Randomized, controlled trials with diverse patient populations — including patients diagnosed with alcohol use disorder — are needed to provide the quality and quantity of data that could be used to support an application for licensing the medication for the treatment of alcohol use disorder,” Le Roux said.
(One such trial is currently underway in Denmark.)
Study implications
With the current medications available to treat alcohol use disorder, the “major problem” is compliance, Le Roux said — “because the cravings for alcohol tend to come in waves.”
“This means a patient might be fully committed to treatment at one point in the week, but then stop taking the medication later in the week when a craving comes,” the professor added.

“This research suggests a promising ancillary benefit of GLP-1 analogs, potentially influencing cravings for alcohol and offering a new avenue for managing alcohol use disorder,” a physician said. (iStock)
There are currently three FDA-approved medications to treat alcohol use disorder: naltrexone (which helps decrease cravings by reducing the “buzz” feeling that comes with drinking alcohol); disulfiram (which helps some people avoid alcohol by making them feel sick when they drink), and acamprosate (which restores the balance of hormones in the brain to reduce cravings), according to the National Institute on Alcohol Abuse and Alcoholism.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
But less than 10% of people with alcohol use disorder get the proper treatment, with many resuming use within the first year of treatment, past research shows.
The main advantage of the GLP-1 agonists is that they only need to be taken once a week and continue to work for the entire week.

For the 188 patients who were followed over an average of four months, none had increased their alcohol intake after starting the weight-loss medications. (iStock)
Outside experts say the study’s findings highlight the potential of weight-loss medications to help treat alcohol use disorder.
“This research suggests a promising ancillary benefit of GLP-1 analogs, potentially influencing cravings for alcohol and offering a new avenue for managing alcohol use disorder,” Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital and Harvard Medical School, who was not part of the study, told Fox News Digital.
For more Health articles, visit www.foxnews.com/health
“While the exact mechanisms are still being explored, the findings contribute to our understanding of the broader benefits of GLP-1 analogs beyond obesity treatment,” Stanford added.
Health
Surgeons Perform First Human Bladder Transplant

Surgeons in Southern California have performed the first human bladder transplant, introducing a new, potentially life-changing procedure for people with debilitating bladder conditions.
The operation was performed earlier this month by a pair of surgeons from the University of California, Los Angeles, and the University of Southern California on a 41-year-old man who had lost much of his bladder capacity from treatments for a rare form of bladder cancer.
“I was a ticking time bomb,” the patient, Oscar Larrainzar, said on Thursday during a follow-up appointment with his doctors. “But now I have hope.”
The doctors plan to perform bladder transplants in four more patients as part of a clinical trial to get a sense of outcomes like bladder capacity and graft complications before pursuing a larger trial to expand its use.
Dr. Inderbir Gill, who performed the surgery along with Dr. Nima Nassiri, called it “the realization of a dream” for treating thousands of patients with crippling pelvic pain, inflammation and recurrent infections.
“There is no question: A potential door has been opened for these people that did not exist earlier,” said Dr. Gill, the chairman of the urology department at U.S.C.
Pushing the Envelope
Until now, most patients who undergo a bladder removal have a portion of their intestine repurposed to help them pass urine. Some receive an ileal conduit, which empties urine into a bag outside the abdomen, while others are given a so-called neobladder, or a pouch tucked inside the body that attaches to the urethra and allows patients to urinate more traditionally.
But bowel tissue, riddled with bacteria, is “inherently contaminated,” Dr. Gill said, and introducing it to the “inherently sterile” urinary tract leads to complications in up to 80 percent of patients, ranging from electrolyte imbalances to a slow reduction in kidney function. The loss of the intestinal segment can also cause new digestive issues.
Dr. Despoina Daskalaki, a transplant surgeon at Tufts Medical Center who was not involved in the new procedure, said advances in transplant medicine (from critical life-sustaining organs, like hearts and livers, to other body parts, like faces, hands, uteri and penises) had led doctors to start “pushing the envelope.”
“They’re asking: ‘Why do we have to put up with all the complications? Why don’t we try and give this person a new bladder?’” Dr. Daskalaki said.
In late 2020, Dr. Nassiri was in his fourth year of residency at the University of Southern California when he and Dr. Gill sat down in the hospital cafeteria to begin brainstorming approaches. After Dr. Nassiri began a fellowship on kidney transplantation at U.C.L.A., the two surgeons continued working together across institutions to test both robotic and manual techniques, practicing first on pigs, then human cadavers, and finally, human research donors who no longer had brain activity but maintained a heartbeat.
One of the challenges of transplanting a bladder was the complex vascular infrastructure. The surgeons needed to operate deep inside the pelvis of the donor to capture and preserve a rich supply of blood vessels so the organ could thrive inside the recipient.
“When we’re removing a bladder because of cancer, we basically just cut them. We do it in less than an hour on a near-daily basis,” Dr. Gill said. “For a bladder donation, that is a significantly higher order of technical intensity.”
The surgeons also chose to conjoin the right and left arteries — as well as the right and left veins — while the organ was on ice, so that only two connections were needed in the recipient, rather than four.
When their strategy was perfected in 2023, the two drew up plans for a clinical trial, which eventually would bring the world’s first recipient: Oscar.
An Ideal First Candidate
When Mr. Larrainzar walked into Dr. Nassiri’s clinic in April 2024, Dr. Nassiri recognized him. Almost four years earlier, Mr. Larrainzar, a husband and father of four, had been navigating end-stage kidney disease and renal cancer, and Dr. Nassiri helped remove both of his kidneys.
But Mr. Larrainzar had also survived urachal adenocarcinoma, a rare type of bladder cancer, and a surgery to resect the bladder tumor had left him “without much of a bladder at all,” Dr. Nassiri said. A normal bladder can hold more than 300 cubic centimeters of fluid; Mr. Larrainzar’s could hold 30.
Now, years of dialysis had begun to fail; fluid was building up inside his body. And with so much scarring in the abdominal region, it would have been difficult to find enough usable length of bowel to pursue another option.
“He showed up serendipitously,” Dr. Nassiri said, “but he was kind of an ideal first candidate for this.”
On a Saturday night earlier this month, Dr. Nassiri received a call about a potential bladder match for Mr. Larrainzar. He and Dr. Gill drove straight to the headquarters of OneLegacy, an organ procurement organization, in Azusa, Calif., and joined a team of seven surgeons working overnight to recover an array of organs from a donor.
The two brought the kidney and bladder to U.C.L.A., then stopped home for a shower, breakfast and a short nap. They completed the eight-hour surgery to give Mr. Larrainzar a new bladder and kidney later that day.
Dr. Nassiri said that kidney transplants can sometimes take up to a week to process urine, but when the kidney and bladder were connected inside Mr. Larrainzar, there was a great connection — “immediate output” — and his creatinine level, which measures kidney function, started to improve immediately. Mr. Larrainzar has already lost 20 pounds of fluid weight since the surgery.
The biggest risks of organ transplantation are the body’s potential rejection of the organ and the side effects caused by the mandatory immune-suppressing drugs given to prevent organ rejection. That is why, for Dr. Rachel Forbes, a transplant surgeon at Vanderbilt University Medical Center who was not involved in the procedure, the excitement is more tempered.
“It’s obviously a technical advance,” she said, but “we already have existing options for people without bladders, and without the downside of requiring immunosuppression.” Unless a patient is — like Mr. Larrainzar — going to be on those medications anyway, “I would be a little bit nervous that you would be exchanging some complications for others,” she said.
A new bladder transplant also does not have nerve connections in the recipient, so while it works well as a storage organ, doctors did not know whether Mr. Larrainzar would ever be able to sense a full bladder, let alone hold and empty it naturally. They spoke about catheters, abdomen maneuvers and eventually developing an on-demand bladder stimulator to help with the release.
But at a follow-up appointment on Thursday morning — just two days after Mr. Larrainzar was discharged from the hospital — Dr. Nassiri removed the catheter and gave him fluids, and Mr. Larrainzar immediately felt that he could urinate.
Dr. Nassiri called it a miracle, then phoned Dr. Gill, who was in a U.S.C. operating room, and exclaimed two words: “He peed!”
“No way! What the hell?” Dr. Gill said. “My jaw is on the floor.”
After finishing the surgery, Dr. Gill drove straight to U.C.L.A. and watched Mr. Larrainzar do it again.
“Of course, this is very, very early. Let’s see how everything goes,” Dr. Gill cautioned. “But it’s the first time he has been able to pee in seven years. For all of us, this is huge.”
Mr. Larrainzar, exhausted, smiled, and Dr. Nassiri brought him a bottle of mineral water to celebrate.
-
Austin, TX1 week ago
Best Austin Salads – 15 Food Places For Good Greens!
-
Technology1 week ago
Mexico is suing Google over how it’s labeling the Gulf of Mexico
-
Politics1 week ago
DHS says Massachusetts city council member 'incited chaos' as ICE arrested 'violent criminal alien'
-
Politics1 week ago
President Trump takes on 'Big Pharma' by signing executive order to lower drug prices
-
Business1 week ago
In-N-Out Burger adds three new California locations to list of 2025 openings
-
News6 days ago
As Harvard Battles Trump, Its President Will Take a 25% Pay Cut
-
Education1 week ago
A Professor’s Final Gift to Her Students: Her Life Savings
-
News1 week ago
Why Trump Suddenly Declared Victory Over the Houthi Militia